Ars Technica·3 min read·medium
As US measles cases rise, biotech firms start developing new treatments
✦AI Summary
Biotech firms are beginning to develop new treatments for measles as US vaccination rates decline and case numbers reach a 35-year high. While these countermeasures aim to protect vulnerable populations, experts note they are years away from availability and may not reach vaccine-hesitant groups.
Vaccines save lives As US measles cases rise, biotech firms start developing new treatments The US is making measles great again, so treatment options are needed for the most vulnerable.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in